NASDAQ:AGEN Agenus (AGEN) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free AGEN Stock Alerts $7.42 +0.96 (+14.86%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$6.32▼$7.7450-Day Range$4.97▼$15.5652-Week Range$4.78▼$42.60Volume1.27 million shsAverage Volume624,441 shsMarket Capitalization$155.45 millionP/E RatioN/ADividend YieldN/APrice Target$130.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Agenus alerts: Email Address Agenus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,652.0% Upside$130.00 Price TargetShort InterestBearish227.78% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.72Based on 3 Articles This WeekInsider TradingAcquiring Shares$325,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($8.21) to ($14.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.00 out of 5 starsMedical Sector175th out of 907 stocksBiological Products, Except Diagnostic Industry21st out of 153 stocks 3.5 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAgenus has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted227.78% of the outstanding shares of Agenus have been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Agenus has recently increased by 4.31%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agenus is -0.93. Previous Next 3.2 News and Social Media Coverage News SentimentAgenus has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agenus this week, compared to 2 articles on an average week.Search InterestOnly 55 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat Follows28 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have bought more of their company's stock than they have sold. Specifically, they have bought $325,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Agenus is held by insiders.Percentage Held by Institutions61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to decrease in the coming year, from ($8.21) to ($14.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. About Agenus Stock (NASDAQ:AGEN)Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More AGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGEN Stock News HeadlinesApril 24, 2024 | finance.yahoo.comBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingApril 23, 2024 | benzinga.comTop 2 Health Care Stocks Which Could Rescue Your Portfolio This Month - Agenus (NASDAQ:AGEN), MultiPlan (NYSE:MPLN)April 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.April 23, 2024 | businesswire.comAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateApril 17, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Agenus (NASDAQ:AGEN)April 13, 2024 | nasdaq.comCommit To Purchase Agenus At $1, Earn 2607.1% Annualized Using OptionsApril 12, 2024 | markets.businessinsider.comSmall-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns LoomApril 12, 2024 | nasdaq.comAgenus Updates Phase 1 Data Of BOT/BAL Therapy In MSS Metastatic Colorectal CancerApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.April 12, 2024 | markets.businessinsider.comAgenus Stock Falls After Reporting Updated Phase 1 Data On Colorectal Cancer TherapyApril 12, 2024 | msn.comAgenus reports updated Phase 1 data on colorectal cancer therapyApril 12, 2024 | finance.yahoo.comAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerApril 12, 2024 | businesswire.comAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerApril 8, 2024 | marketwatch.comMiNK Therapeutics' MiNK-215 Data Show Potential Treatment for Liver MetastasesApril 8, 2024 | fool.comDown 75%. Is Agenus Stock a Buy on the Dip?April 7, 2024 | investing.comAgenus announces reverse stock split to meet Nasdaq requirementsApril 5, 2024 | businesswire.comAgenus Announces Reverse Stock Split of Common StockApril 3, 2024 | fool.com2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?March 24, 2024 | investorplace.com3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 MillionMarch 20, 2024 | ca.finance.yahoo.comAGEN Aug 2024 2.000 putMarch 17, 2024 | finance.yahoo.comUS$5.50: That's What Analysts Think Agenus Inc. (NASDAQ:AGEN) Is Worth After Its Latest ResultsMarch 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Agenus Amidst Promising Cancer Immunotherapy Developments and Strategic Financial MovesMarch 15, 2024 | benzinga.comEarnings Preview For AgenusMarch 15, 2024 | finance.yahoo.comAgenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comAnalysts Just Shaved Their Agenus Inc. (NASDAQ:AGEN) Forecasts DramaticallyMarch 15, 2024 | ca.finance.yahoo.comAGEN Mar 2024 2.000 putMarch 14, 2024 | markets.businessinsider.comAgenus Poised for Growth: Anticipated BLA Filing and Promising Clinical Data Underpin Buy RatingSee More Headlines Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/24/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AGEN CUSIP00847G70 CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees389Year FoundedN/APrice Target and Rating Average Stock Price Target$130.00 High Stock Price Target$160.00 Low Stock Price Target$100.00 Potential Upside/Downside+1,652.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($14.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,760,000.00 Net Margins-164.69% Pretax Margin-164.69% Return on EquityN/A Return on Assets-71.22% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual Sales$156.31 million Price / Sales0.99 Cash FlowN/A Price / Cash FlowN/A Book Value($7.78) per share Price / Book-0.95Miscellaneous Outstanding Shares20,950,000Free Float19,941,000Market Cap$155.45 million OptionableOptionable Beta1.26 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Founder, Executive Chairman & CEO Comp: $1.34MMs. Christine M. Klaskin (Age 58)VP of Finance, Principal Financial Officer & Principal Accounting Officer Comp: $407.44kDr. Steven J. O'Day M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $970.98kCraig WinterChief Information OfficerMr. Zack ArmenHead of Investor RelationsMs. Tracy Mazza ClementeChief People OfficerMr. Dhan ChandScientific Director & Head of Drug DiscoveryMr. Alfred DadsonChief Manufacturing OfficerMr. Eric HumesChief Quality OfficerDr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic AdvisorMore ExecutivesKey CompetitorsSangamo TherapeuticsNASDAQ:SGMOCurisNASDAQ:CRISAligos TherapeuticsNASDAQ:ALGSPoseida TherapeuticsNASDAQ:PSTXSAB BiotherapeuticsNASDAQ:SABSView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 13,604 shares on 4/17/2024Ownership: 2.666%Powell Investment Advisors LLCBought 43,500 shares on 4/16/2024Ownership: 1.162%Key Client Fiduciary Advisors LLCBought 236,500 shares on 4/15/2024Ownership: 4.100%Los Angeles Capital Management LLCSold 25,540 shares on 4/5/2024Ownership: 0.042%Ables Iannone Moore & Associates Inc.Bought 79,000 shares on 3/14/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions AGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Agenus stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGEN shares. View AGEN analyst ratings or view top-rated stocks. What is Agenus' stock price target for 2024? 3 equities research analysts have issued 1 year target prices for Agenus' stock. Their AGEN share price targets range from $100.00 to $160.00. On average, they expect the company's stock price to reach $130.00 in the next twelve months. This suggests a possible upside of 1,652.0% from the stock's current price. View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts. How have AGEN shares performed in 2024? Agenus' stock was trading at $16.5580 at the beginning of the year. Since then, AGEN stock has decreased by 55.2% and is now trading at $7.42. View the best growth stocks for 2024 here. When is Agenus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our AGEN earnings forecast. How can I listen to Agenus' earnings call? Agenus will be holding an earnings conference call on Tuesday, May 7th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) posted its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $2.20. The biotechnology company had revenue of $83.80 million for the quarter, compared to the consensus estimate of $54.21 million. When did Agenus' stock split? Shares of Agenus reverse split before market open on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Garo H. Armen's approval rating as Agenus' CEO? 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL). Who are Agenus' major shareholders? Agenus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (4.10%), Hennion & Walsh Asset Management Inc. (2.67%), Powell Investment Advisors LLC (1.16%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Garo H Armen and Steven J O'day. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AGEN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
